548 related articles for article (PubMed ID: 8930810)
61. [Cyclic AMP-specific nucleotide phosphodiesterase from the insoluble fraction of the human brain].
Kireeva NN; Bobruskin ID; Severin SE
Biokhimiia; 1995 May; 60(5):694-708. PubMed ID: 7662796
[TBL] [Abstract][Full Text] [Related]
62. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
63. Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.
Silver PJ; Allen P; Etzler JH; Hamel LT; Bentley RG; Pagani ED
Second Messengers Phosphoproteins; 1990; 13(1):13-25. PubMed ID: 2286932
[TBL] [Abstract][Full Text] [Related]
64. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
65. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
[TBL] [Abstract][Full Text] [Related]
66. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
67. Correlation of cell-free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices.
Whalin ME; Garrett RL; Thompson WJ; Strada SJ
Second Messengers Phosphoproteins; 1988-1989; 12(5-6):311-25. PubMed ID: 2856115
[TBL] [Abstract][Full Text] [Related]
68. Effects of fatty acids on activity of cGMP-stimulated cyclic nucleotide phosphodiesterase from calf liver.
Yamamoto T; Yamamoto S; Manganiello VC; Vaughan M
Arch Biochem Biophys; 1984 Feb; 229(1):81-9. PubMed ID: 6322693
[TBL] [Abstract][Full Text] [Related]
69. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
70. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.
Carceles MD; Aleixandre F; Fuente T; López-Vidal J; Laorden ML
Eur J Anaesthesiol; 2003 Mar; 20(3):205-11. PubMed ID: 12650491
[TBL] [Abstract][Full Text] [Related]
71. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
72. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
73. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
[TBL] [Abstract][Full Text] [Related]
74. The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task.
Giorgi M; Modica A; Pompili A; Pacitti C; Gasbarri A
Behav Brain Res; 2004 Sep; 154(1):99-106. PubMed ID: 15302115
[TBL] [Abstract][Full Text] [Related]
75. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
[TBL] [Abstract][Full Text] [Related]
76. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
77. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
78. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
79. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells.
Leroy MJ; Degerman E; Taira M; Murata T; Wang LH; Movsesian MA; Meacci E; Manganiello VC
Biochemistry; 1996 Aug; 35(31):10194-202. PubMed ID: 8756484
[TBL] [Abstract][Full Text] [Related]
80. [Effect of several hormones on cyclic 3',5'-nucleotide phosphodiesterase in rat kidneys].
Iwase K
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1678-91. PubMed ID: 6319206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
